



Divi's Laboratories Limited

Date: August 12, 2024

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir/ Madam,

Sub: Proceedings of 34th Annual General Meeting (AGM), Voting Results and Report of Scrutinizer

This is to inform that the 34th Annual General Meeting (AGM) of the Company was held on August 12, 2024 at 10.00 a.m. through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”) and the business mentioned in the Notice convening the AGM dated August 12, 2024 was duly transacted.

In this regard, we hereby submit the following:

1. Summary of proceedings of the 34th Annual General Meeting along with copy of the Chairman’s speech and Managing Director’s speech delivered at the AGM as **Annexure – I**;
2. Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as **Annexure – II**;
3. The Report of Scrutinizer on remote e-voting and voting at AGM (by electronic means) as **Annexure – III**.

Please note that all the resolutions set out in the Notice of 34th AGM were passed with requisite majority.

This is for your information and records.

Yours faithfully,
For **Divi's Laboratories Limited**

M. Satish Choudhury
Company Secretary & Compliance Officer



Divi's Laboratories Limited

ANNEXURE – I

Summary of proceedings of the 34th Annual General Meeting of Divi's Laboratories Limited held on Monday, August 12, 2024, at 10.00 a.m. (IST) through Video Conferencing /Other Audio-Visual Means

Directors present through Video Conferencing (VC) / Other Audio-Visual Means (OAVM):

1. Dr. Ramesh B.V. Nimmagadda - Chairman & Independent Director, Chairman of Stakeholders Relationship Committee and CSR Committee participated from Chennai, India
2. Dr. Murali K. Divi - Managing Director participated from Hyderabad, India
3. Mr. N.V. Ramana - Executive Director participated from Hyderabad, India
4. Dr. Kiran S. Divi - Whole-time Director & Chief Executive Officer participated from Hyderabad, India
5. Ms. Nilima Prasad Divi - Whole-time Director (Commercial) participated from Hyderabad, India
6. Dr. S. Devendra Rao - Whole-time Director (Manufacturing) participated from Visakhapatnam, India
7. Dr. S. Ganapaty - Independent Director and Chairman of Nomination and Remuneration Committee participated from Visakhapatnam, India
8. Prof. Sunaina Singh - Independent Director participated from California, USA
9. Mr. K.V. Chowdary - Independent Director and Chairman of Audit Committee participated from Hyderabad, India
10. Dr. Rajendra Kumar Premchand - Independent Director participated from Hyderabad, India

In attendance of the following persons present through VC / OAVM participated in the meeting:

S. No.	Name	Designation	Location
1.	Mr. L. Kishore Babu	- Chief Financial Officer	Hyderabad, India
2.	Mr. M. Satish Choudhury	- Company Secretary & Compliance Officer	Hyderabad, India
3.	Mr. N.K. Varadarajan	- Partner, Price Waterhouse Chartered Accountants LLP, Statutory Auditors	Mumbai, India
4.	Mr. V. Bhaskara Rao	- Secretarial Auditor	Hyderabad, India

Members Present:

The meeting was attended by 207 members through VC or OAVM.

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854

E-mail : mail@divislabs.com, Website : www.divislabs.com



Divi's Laboratories Limited

Dr. Ramesh B.V. Nimmagadda, Chairman of the Company, chaired the meeting and conducted the proceedings of the meeting. The requisite quorum being present, the Chairman called the meeting to order.

Mr. M. Satish Choudhury, Company Secretary informed the members about general instructions regarding participation and voting at this meeting. He informed that the Annual General Meeting (AGM) was held through VC or OAVM in accordance with the Companies Act, 2013 and circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. Accordingly, the Company has provided the facility for the members for joining the meeting through VC or OAVM. It was informed that the Company has also provided webcast facility to view the live proceedings of the AGM.

The Register of Directors and Key Managerial Personnel, the Register of Contracts or Arrangements in which Directors are interested, were made available electronically for inspection by the members during the AGM.

Members were informed that the Company had provided the facility to cast the votes electronically, on all resolutions set forth in the Notice of AGM; and Members who have not cast their votes electronically and were participating in the meeting can cast their votes during the meeting through the e-voting system (Insta Poll) provided by Kfin Technologies Limited (Kfin).

The Chairman outlined the pharma industry outlook and the Managing Director briefed the meeting on the Company's operations during the year 2023-24 and during the first quarter of the year 2024-25 and outlook; beside updating about dividend and CSR initiatives by the Company. A copy of the Chairman's speech and Managing Director's speech are enclosed herewith.

The Company Secretary provided summary of the Statutory Auditor's Report and Secretarial Auditor's Report and informed that there were no qualifications, observations or adverse comments on financial statements and matters, which have any material bearing on the functioning of the Company.

The Annual Report for the year ended March 31, 2024, along with Notice of this meeting, Board's Report, Auditor's Reports, and the Audited Financial Statements of the Company as circulated to the members, were taken as read.

The remote e-Voting period commenced at 9 a.m. (IST) on Thursday, August 08, 2024, and the facility was available to the shareholders till 5 p.m. (IST) on Sunday, August 11, 2024. It was also informed that there would be no voting by show of hands at the meeting.

It was also informed that the Board of Directors has appointed Mr. V. Bhaskara Rao or failing him Mr. S. Hari Kishore Babu, Practicing Company Secretaries, as the Scrutinizer for scrutiny of the votes cast through the remote e-voting platform and e-voting during the AGM.

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854

E-mail : mail@divislabs.com, Website : www.divislabs.com



Divi's Laboratories Limited

The following items of business as set out in the Notice convening the 34th Annual General Meeting were commended for Members' consideration and approval:

S.No	Resolutions Description	Type of resolution
Ordinary Business		
1	To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2024, and the reports of the Board of Directors' and Auditors' thereon.	Ordinary
2	To declare dividend of ₹30/- per equity share of face value ₹2/- each (i.e. @ 1,500%) for the financial year ended March 31, 2024.	Ordinary
3	To appoint a director in place of Mr. N.V. Ramana (DIN: 00005031), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.	Ordinary
4	To appoint a director in place of Dr. Kiran S. Divi (DIN: 00006503), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.	Ordinary
Special Business		
5	To appoint Dr. Rajendra Kumar Premchand, (DIN: 00895990), as an Independent Director of the Company w.e.f. May 25, 2024.	Special
6	To re-appoint Dr. Murali K. Divi (DIN: 00005040) as Managing Director of the Company w.e.f. October 10, 2024.	Special
7	To re-appoint Mr. N.V. Ramana (DIN: 00005031) as Executive Director of the Company w.e.f. December 26, 2024.	Special
8	To re-appoint Mr. K.V. Chowdary (DIN: 08485334) as an Independent Director of the Company w.e.f. January 04, 2025.	Special

The Chairman formally announced e-voting during the Meeting for all those shareholders who have not cast their votes earlier, through Insta Poll provided by Kfin, in respect of all the resolutions as set out in the Notice convening this AGM.

The Chairman opened the Question and Answers session. The Members registered as speakers asked their queries and expressed their views. The Managing Director summarised his response to the queries of the Members.

The Chairman authorized the Company Secretary to declare the results of the voting and place the results on the website of the Company and on website of Kfin at the earliest, besides submitting the same to the Stock Exchanges i.e., NSE and BSE. He informed that the resolutions, as set forth in the Notice, shall be deemed to be passed today subject to receipt of requisite number of votes.

The Chairman announced that all the business set out in the Notice of the AGM has been concluded and a time period of 15 minutes would be available for voting at the meeting on the Kfin's Insta-poll after which the meeting will stand closed. He thanked the Members for attending the meeting. It was confirmed that the requisite quorum was present throughout the meeting.

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854

E-mail : mail@divislabs.com, Website : www.divislabs.com



Divi's Laboratories Limited

The Annual General Meeting was concluded at 11.25 a.m. (IST) on August 12, 2024.

The Scrutinizers' Report was received on August 12, 2024, and accordingly, all the resolutions set out in the Notice of the 34th Annual General Meeting of the Company dated May 25, 2024, were declared as passed with requisite majority.

For Divi's Laboratories Limited

**M. Satish Choudhury
Company Secretary & Compliance Officer**

(Enclosures: Chairman's Speech and Managing Director's Speech)

DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: Divi Towers, 1-72/23(P)/DIVIS/303,

Cyber Hills, Gachibowli, Hyderabad - 500 032, INDIA

Tel: +91-40-6696 6300, Fax: +91-40-6696 6460

E-mail: cs@divislabs.com, Website: www.divislabs.com

34th Annual General Meeting, 12th August 2024

CHAIRMAN'S SPEECH

Dear Shareholders and esteemed members of the Board,

Good morning and welcome to the 34th Annual General Meeting of Divi's Laboratories Limited. I extend my warmest greetings to each one of you, and hope that you and your loved ones are in good health.

The Annual Report for the year ended 31st March 2024, along with the meeting notice, Board's Report, and the Company's audited financial statements, have been duly circulated to you. With your permission, I take them as read. As we gather today, we greatly appreciate your generous support, and on behalf of the Board of Directors, I thank you for your valuable time and participation.

The financial year 2023-24 has been marked by significant global events, leading to market volatility as well as creating room for notable shifts in the pharmaceutical industry. These changes, driven by global disruptions, volatile trade conditions, evolving healthcare and security policies, technological advancements, and the emergence of innovative therapies, have created new opportunities for growth.

According to IQVIA Inc., the global pharmaceutical market is expected to reach \$2.3 trillion by 2028, growing at a CAGR of 6-9%, surpassing previous projections by \$400 billion. Over the next five years, around 350 novel active substances (NAS) are set to enter the market, predominantly in oncology, obesity, diabetes, cardiovascular, and neurology. The upcoming loss of exclusivity (LOE) will also substantially affect the industry. While established markets may experience slower growth, emerging markets are expected to witness increased volume and spending due to larger population and enhanced accessibility.

Grand View Research reports that the global API market, valued at \$237.47 billion in 2023, is growing at a CAGR of 5.75% from 2024 to 2030, driven by the widespread adoption of generic drugs. The innovative API market is expected to reach \$209.5 billion by 2030, growing at a CAGR of 5.8%, while the generic API market is projected to reach \$114.6 billion by 2030, growing at a CAGR of 6.2% from 2022 to 2030. Additionally, the global CDMO market, valued at \$100.4 billion in 2023, is expected to grow at a CAGR of 7.4% from 2024 to 2030, driven by the increasing prevalence of chronic diseases and demand for specialised treatments and advanced manufacturing technologies.

The Indian pharmaceutical industry continues its positive trend with quality manufacturing, drug affordability, and technology advancement. As of the latest reporting period, India ranks third globally in pharmaceutical production by volume with a consistent growth trajectory at a CAGR of 9.43% over the past nine years. The domestic pharmaceutical market was valued at \$49.78 billion in FY23, by the India Brand Equity Foundation (IBEF). An EY FICCI report predicts India's pharmaceutical market to reach \$130 billion by 2030, reflecting significant growth prospects. According to PharmExcil, the industry's growth was further driven by India's pharmaceutical exports, which rose by 10% to \$27.8 billion in FY24, propelled by double-digit growth in the US and UK generics markets.

Furthermore, Grand View Research estimates the Indian Active Pharmaceutical Ingredient (API) market to be \$18.29 billion in 2023, with expected growth at a CAGR of 7.7% from 2024 to 2030. APIs are crucial to India's pharmaceutical sector, accounting for over half of the country's pharmaceutical exports. India has become the preferred destination for high-value and complex APIs, reaffirming its role as a reliable global API supplier. In addition, the Indian nutraceuticals market, estimated at \$26.87 billion in 2023, is projected to grow at a CAGR of 13.5% from 2024 to 2030, driven by increasing health consciousness, changing consumer lifestyles, and rising



health-related incidences. The Indian pharmaceutical industry remains poised for sustained growth, driven by innovation, developmental and infrastructural investments, government support, and evolving market dynamics.

Your Company has successfully executed its capex initiatives and is rapidly progressing with the 200-acre Phase I construction activities in the Unit-3 manufacturing facility at Kakinada. Divi's has efficiently implemented fast-track projects and entered into long-term agreements while adhering to stringent environmental and safety regulations. Despite global challenges, your Company has maintained efficient and sustainable operations, mitigated all sourcing risks, and proactively reinforced the supply chains. I commend Divi's Management for their continued dedication to steering the Company towards success.

Thank You.

I would now request Dr. Murali Divi, our Managing Director to address the shareholders.

Dr. Ramesh Nimmagadda

Chairman

DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: Divi Towers, 1-72/23(P)/DIVIS/303,

Cyber Hills, Gachibowli, Hyderabad - 500 032, INDIA

Tel: +91-40-6696 6300, Fax: +91-40-6696 6460

E-mail: cs@divislabs.com, Website: www.divislabs.com

34th Annual General Meeting, 12th August 2024

MANAGING DIRECTOR'S SPEECH

Ladies and Gentlemen,

Good morning to each one of you and a hearty welcome to the 34th Annual General Meeting of Divi's Laboratories.

The financial year 2023-24 has been transformative for Divi's Laboratories, marking significant progress in the construction of Unit-3 manufacturing facility and expanding prospects across its "Six Growth Engines". Despite a year filled with global crises, your Company's commitment to resilience and operational excellence has enabled it to turn challenges into opportunities.

During the financial year, worldwide geopolitical crises resulted in numerous challenges such as trade disruptions, supply chain vulnerabilities, logistical challenges, inflation, and cost volatility. Despite these obstacles, the Indian pharmaceutical industry has demonstrated resilience and adaptability, upholding its position as one of the largest pharmaceutical suppliers globally.

The current geopolitical landscape, while volatile, is also facilitating advancements in the pharmaceutical industry. Divi's has proactively navigated these dynamics, optimising its performance and reinforcing its business model. This model, strengthened by expanded capacities, product diversification, process efficiency, and project execution, has long been driving your Company to capitalise on trends and create shared value for all stakeholders. Strategic supply chain management, backward integration, continuous process innovation, efficient inventory management, and supply base diversification have positioned your Company advantageously, helping it grow and mitigate global adversities.

Your Company's focus on environmental sustainability, ensuring resource efficiency, and implementing Green Chemistry principles throughout its processes, has further enhanced its position as a sustainable global API supplier. Looking ahead, Divi's remains steadfast in its commitment to responsible growth, and the strategic pursuit of new ventures across various portfolios. With its extensive capacities, more than three decades of chemistry expertise, and execution excellence, Divi's is well-prepared to embrace emerging opportunities. Your Company remains dedicated to delivering the highest quality APIs and sustaining its valuable partnerships while ensuring shared value creation for all stakeholders.

OPERATIONS FOR THE YEAR

Your Company has been resilient and adaptable in ensuring efficient supply chain operations and reliably meeting all customer requirements with agility and foresight. During the year, Divi's Unit-1 manufacturing facility at Hyderabad was visited by the US FDA Commissioner and his team, who recognised your Company's commitment to excellence and applauded the magnitude of its operations, high regulatory standards, and quality systems. Your Company has consistently adhered to Good Manufacturing Practices (cGMP) for the past 25 years, evident in numerous global regulatory inspections.

The Unit-3 greenfield project construction is advancing seamlessly and the upcoming production activity in the 200 acres Phase-I is expected to gradually commence during FY 2024-25. Divi's also witnessed consistent value realisation from its existing custom synthesis commercial projects and is advancing with several new projects across all clinical phases in this portfolio. With a continued focus on the expanding peptide space, your Company is not only manufacturing peptide building blocks but is also pursuing the production of peptide fragments required for various

GLP-I and GLP-II compounds. In terms of regulatory filings, your Company submitted a total of 42 Drug Master Files in the financial year 2023-24.

Additionally, Divi's has initiated the process of entering into a long-term supply agreement with a customer, with plans for capacity addition at its manufacturing facility with an estimated investment between ₹650 crores to ₹700 crores, to be funded from internal accruals. The proposed facility is expected to be operational around January 2027.

Some of the highlights of the operations for the year 2023-24 are:

- ▶ Our consolidated total income for the year was ₹8,184 crores.
- ▶ Profit Before Tax (PBT) for the year was ₹2,163 crores.
- ▶ Tax Provision for the current year amounted to ₹563 crores as against ₹545 crores for the previous year.
- ▶ Profit After Tax (PAT) for the year summed up to ₹1,600 crores.
- ▶ Earnings Per Share of 2/- each works out to ₹60.27 for the year.
- ▶ Out of the total revenue, exports accounted for 87%.

DIVIDEND

Your Board is pleased to recommend a dividend of ₹30 per equity share, i.e., 1,500% for the financial year ended March 31, 2024. The total dividend payout for the current year amounts to ₹796 crores.

OPERATIONS FOR QUARTER ENDED 30th JUNE 2024

Divi's had a successful US FDA cGMP inspection at its Unit-2 manufacturing facility in Visakhapatnam, which was completed with one procedural observation- an outcome reflective of your Company's stringent compliance across all operations. Despite volatile global dynamics including logistical and supply chain challenges, ongoing geopolitical tensions, and persistent pricing pressures, that continue to impact the pharmaceutical industry, Divi's remained resilient and efficiently fulfilled all commitments to your customers.

In response to global crises, Divi's has diligently monitored all shipments for both procurement and exports and implemented risk mitigation measures, including streamlining inventory management, advancing shipping schedules, maintaining safety stocks for extended periods, and diversifying the supply base for key raw materials, to ensure continuity and efficiency.

During the first quarter of the year 2024-25, your Company earned a consolidated total income of ₹2,197 crores, a profit before tax of ₹604 crores, and a profit after tax of ₹430 crores."

CSR INITIATIVES

Divi's prioritises environmental sustainability and consistently upholds responsible operations, while actively engaging in community-building efforts. Your Company has been pursuing CSR initiatives aimed at making meaningful contributions to communities and facilitating their sustainable growth.

Throughout the year, Divi's has worked on holistic rural development by actively undertaking infrastructural improvements, road developments, and sanitisation system renovations in villages across Telangana and Andhra Pradesh. Additionally, Divi's has been conducting plantation drives to increase afforestation and enhance the green cover in and around the manufacturing units.

Your Company also focuses on enhancing rural communities by providing safe drinking water, improving access to primary healthcare, and promoting animal welfare in villages. Divi's aims to address the challenges faced by these

underprivileged communities, with a primary focus on women, children, and differently abled individuals, and empower them through livelihood improvements and other targeted interventions – all in the pursuit of making a positive impact around us.

The CSR Expenditure incurred during the year benefitted over 12,28,000 people. I would like to highlight some of the notable CSR programmes that were undertaken:

- ▼ The flagship initiative for safe drinking water, Project Sujalam, benefitted over 5,56,000 individuals in 1,120 locations, and ~3,72,000 individuals in 16 locations every day via Projects Jalaprasadam.
- ▼ Divi's core initiative focused on the holistic development and empowerment of children through infrastructural development, nutrition enhancement, and provision of amenities, has made a tangible impact on the lives of over 1 lakh students in more than 1,000 schools across Telangana and Andhra Pradesh.
- ▼ Initiatives focused on empowering the differently abled individuals in FY24 involved the infrastructural upgradation of Government ITI College for Differently Abled Boys and regular maintenance of the Government School for the Visually Challenged Girls in Visakhapatnam.
- ▼ ~31,000 saplings were planted, promoting ecological balance, and increasing green cover across 7 villages in FY24.
- ▼ The initiative on enhancing rural healthcare covered 50 villages and benefitted ~1,89,500 individuals in FY24.
- ▼ Livelihood generation programmes helped upskill ~500 women across 5 villages.
- ▼ Animal welfare initiatives reached ~22,000 farmers across Choutuppal and Bheemili Mandal.
- ▼ Village development and rural livelihood enhancement initiative aided in uplifting the rural communities and successfully empowered 2.5 lakh individuals across 44 villages surrounding Divi's manufacturing units.

CONCLUSION

Ladies and Gentlemen, on behalf of the Board, I would like to thank all our stakeholders- esteemed customers, vendors, business associates, banks, regulatory agencies, government departments, and our shareholders, for their continued trust and support. Your goodwill and encouragement have been instrumental to our success over the past three decades. It is your confidence in Divi's that helps us reaffirm our commitment to excellence and sustainable growth.

Thank You.

Dr. Murali K. Divi

Managing Director

ANNEXURE - II

	DIVI'S LABORATORIES LIMITED
Date of the AGM/EGM	12-08-2024
Total number of shareholders on record date	298324
No. of shareholders present in the meeting either in person or through proxy:	
Promoters and Promoter Group:	Not Applicable
Public:	Not Applicable
No. of Shareholders attended the meeting through Video Conferencing	
Promoters and Promoter Group:	3
Public:	204

Resolution No.	1									
Resolution required: (Ordinary/ Special)	ORDINARY - To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2024, and the reports of the Board of Directors' and Auditors' thereon.									
Whether promoter/ promoter group are interested in the agenda/resolution?	No									
Category	Mode of Voting	No. of shares held (1)	No. of votes polled (2)	% of Votes Polled on outstanding shares (3)=[(2)/(1)]* 100	No. of Votes – in favour (4)	No. of Votes – against (5)	% of Votes in favour on votes polled (6)=[(4)/(2)]*100	% of Votes against on votes polled (7)=[(5)/(2)]*100	Votes Invalid	Votes Abstained
Promoter and Promoter Group	E-Voting	13,77,72,090	13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
Public- Institutions	E-Voting	10,10,08,456	8,77,99,252	86.9227	8,77,98,492	760	99.9991	0.0008	0	1,22,265
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		8,77,99,252	86.9227	8,77,98,492	760	99.9991	0.0009	0	122,265
Public- Non Institutions	E-Voting	2,66,88,034	18,13,244	6.7942	18,13,083	161	99.9911	0.0088	0	490
	Poll		11,29,952	4.2339	11,29,952	0	100.0000	0.0000	0	4,990
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		29,43,196	11.0281	29,43,035	161	99.9945	0.0055	0	5,480
Total		26,54,68,580	22,85,14,448	86.0797	22,85,13,527	921	99.9996	0.0004	0	127,745

Resolution No.	2									
Resolution required: (Ordinary/ Special)	ORDINARY - To declare dividend of 30/- per equity share of face value 2/- each (i.e. @ 1,500%) for the financial year ended March 31, 2024.									
Whether promoter/ promoter group are interested in the agenda/resolution?	No									
Category	Mode of Voting	No. of shares held (1)	No. of votes polled (2)	% of Votes Polled on outstanding shares (3)=[(2)/(1)]* 100	No. of Votes – in favour (4)	No. of Votes – against (5)	% of Votes in favour on votes polled (6)=[(4)/(2)]*100	% of Votes against on votes polled (7)=[(5)/(2)]*100	Votes Invalid	Votes Abstained
Promoter and Promoter Group	E-Voting	13,77,72,090	13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
Public- Institutions	E-Voting	10,10,08,456	8,78,58,613	86.9814	8,73,63,154	4,95,459	99.4360	0.5639	0	62,904
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		8,78,58,613	86.9814	8,73,63,154	4,95,459	99.4361	0.5639	0	62904
Public- Non Institutions	E-Voting	2,66,88,034	18,13,256	6.7943	18,13,027	229	99.9873	0.0126	0	478
	Poll		11,29,952	4.2339	11,29,952	0	100.0000	0.0000	0	4,990
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		29,43,208	11.0282	29,42,979	229	99.9922	0.0078	0	5468
Total		26,54,68,580	22,85,73,821	86.1020	22,80,78,133	4,95,688	99.7831	0.2169	0	68372

Resolution No.	3									
Resolution required: (Ordinary/ Special)	ORDINARY - To appoint a director in place of Mr. N.V. Ramana (DIN: 00005031), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment									
Whether promoter/ promoter group are interested in the agenda/resolution?	No									
Category	Mode of Voting	No. of shares held (1)	No. of votes polled (2)	% of Votes Polled on outstanding shares (3)=[(2)/(1)]* 100	No. of Votes – in favour (4)	No. of Votes – against (5)	% of Votes in favour on votes polled (6)=[(4)/(2)]*100	% of Votes against on votes polled (7)=[(5)/(2)]*100	Votes Invalid	Votes Abstained
Promoter and Promoter Group	E-Voting	13,77,72,090	13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
Public- Institutions	E-Voting	10,10,08,456	8,71,58,454	86.2883	8,64,62,218	6,96,236	99.2011	0.7988	0	7,63,063
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		8,71,58,454	86.2883	8,64,62,218	6,96,236	99.2012	0.7988	0	763063
Public- Non Institutions	E-Voting	2,66,88,034	18,13,244	6.7942	18,09,920	3,324	99.8166	0.1833	0	490
	Poll		11,29,952	4.2339	11,29,952	0	100.0000	0.0000	0	4,990
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		29,43,196	11.0281	29,39,872	3,324	99.8871	0.1129	0	5480
Total		26,54,68,580	22,78,73,650	85.8383	22,71,74,090	6,99,560	99.6930	0.3070	0	768543

Resolution No.	4									
Resolution required: (Ordinary/ Special)	ORDINARY - To appoint a director in place of Dr. Kiran S. Divi (DIN: 00006503), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment									
Whether promoter/ promoter group are interested in the agenda/resolution?	Yes									
Category	Mode of Voting	No. of shares held (1)	No. of votes polled (2)	% of Votes Polled on outstanding shares (3)=[(2)/(1)]* 100	No. of Votes – in favour (4)	No. of Votes – against (5)	% of Votes in favour on votes polled (6)=[(4)/(2)]*100	% of Votes against on votes polled (7)=[(5)/(2)]*100	Votes Invalid	Votes Abstained
Promoter and Promoter Group	E-Voting	13,77,72,090	13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0.0000	0
Public- Institutions	E-Voting	10,10,08,456	8,78,42,454	86.9654	8,75,80,757	2,61,697	99.7020	0.2979	0	79,063
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		8,78,42,454	86.9654	8,75,80,757	2,61,697	99.7021	0.2979	0	79063
Public- Non Institutions	E-Voting	2,66,88,034	18,13,244	6.7942	18,09,920	3,324	99.8166	0.1833	0	490
	Poll		11,29,952	4.2339	11,29,952	0	100.0000	0.0000	0	4,990
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		29,43,196	11.0281	29,39,872	3,324	99.8871	0.1129	0	5480
Total		26,54,68,580	22,85,57,650	86.0959	22,82,92,629	2,65,021	99.8840	0.1160	0	84543

Resolution No.	5									
Resolution required: (Ordinary/ Special)	SPECIAL - To appoint Dr. Rajendra Kumar Premchand, (DIN: 00895990), as an Independent Director of the Company w.e.f. May 25, 2024.									
Whether promoter/ promoter group are interested in the agenda/resolution?	No									
Category	Mode of Voting	No. of shares held (1)	No. of votes polled (2)	% of Votes Polled on outstanding shares (3)=[(2)/(1)]* 100	No. of Votes – in favour (4)	No. of Votes – against (5)	% of Votes in favour on votes polled (6)=[(4)/(2)]*100	% of Votes against on votes polled (7)=[(5)/(2)]*100	Votes Invalid	Votes Abstained
Promoter and Promoter Group	E-Voting	13,77,72,090	13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
Public- Institutions	E-Voting	10,10,08,456	8,71,58,454	86.2883	8,70,09,412	1,49,042	99.8289	0.1710	0	7,63,063
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		8,71,58,454	86.2883	8,70,09,412	1,49,042	99.8290	0.1710	0	763063
Public- Non Institutions	E-Voting	2,66,88,034	18,13,244	6.7942	18,09,910	3,334	99.8161	0.1838	0	490
	Poll		11,29,952	4.2339	11,29,952	0	100.0000	0.0000	0	4,990
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		29,43,196	11.0281	29,39,862	3,334	99.8867	0.1133	0	5480
Total	26,54,68,580	22,78,73,650	85.8383	22,77,21,274	1,52,376	99.9331	0.0669	0	768543	

Resolution No.	6									
Resolution required: (Ordinary/ Special)	SPECIAL - To re-appoint Dr. Murali K. Divi (DIN: 00005040) as Managing Director of the Company w.e.f. October 10, 2024.									
Whether promoter/ promoter group are interested in the agenda/resolution?	Yes									
Category	Mode of Voting	No. of shares held (1)	No. of votes polled (2)	% of Votes Polled on outstanding shares (3)=[(2)/(1)]* 100	No. of Votes – in favour (4)	No. of Votes – against (5)	% of Votes in favour on votes polled (6)=[(4)/(2)]*100	% of Votes against on votes polled (7)=[(5)/(2)]*100	Votes Invalid	Votes Abstained
Promoter and Promoter Group	E-Voting	13,77,72,090	13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
Public- Institutions	E-Voting	10,10,08,456	8,78,42,454	86.9654	6,19,70,375	2,58,72,079	70.5471	29.4528	0	79,063
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		8,78,42,454	86.9654	6,19,70,375	2,58,72,079	70.5472	29.4528	0	79063
Public- Non Institutions	E-Voting	2,66,88,034	18,13,244	6.7942	18,12,923	321	99.9822	0.0177	0	490
	Poll		11,29,952	4.2339	11,29,952	0	100.0000	0.0000	0	4,990
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		29,43,196	11.0281	29,42,875	321	99.9891	0.0109	0	5480
Total	26,54,68,580	22,85,57,650	86.0959	20,26,85,250	2,58,72,400	88.6801	11.3199	0	84543	

Resolution No.	7									
Resolution required: (Ordinary/ Special)	SPECIAL - To re-appoint Mr. N.V. Ramana (DIN: 00005031) as Executive Director of the Company w.e.f. December 26, 2024.									
Whether promoter/ promoter group are interested in the agenda/resolution?	No									
Category	Mode of Voting	No. of shares held (1)	No. of votes polled (2)	% of Votes Polled on outstanding shares (3)=[(2)/(1)]* 100	No. of Votes – in favour (4)	No. of Votes – against (5)	% of Votes in favour on votes polled (6)=[(4)/(2)]*100	% of Votes against on votes polled (7)=[(5)/(2)]*100	Votes Invalid	Votes Abstained
Promoter and Promoter Group	E-Voting	13,77,72,090	13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
Public- Institutions	E-Voting	10,10,08,456	8,78,42,454	86.9654	6,70,56,088	2,07,86,366	76.3367	23.6632	0	79,063
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		8,78,42,454	86.9654	6,70,56,088	2,07,86,366	76.3368	23.6632	0	79063
Public- Non Institutions	E-Voting	2,66,88,034	18,13,244	6.7942	18,12,918	326	99.9820	0.0179	0	490
	Poll		11,29,952	4.2339	11,29,952	0	100.0000	0.0000	0	4,990
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		29,43,196	11.0281	29,42,870	326	99.9889	0.0111	0	5480
Total		26,54,68,580	22,85,57,650	86.0959	20,77,70,958	2,07,86,692	90.9053	9.0947	0	84543

Resolution No.	8									
Resolution required: (Ordinary/ Special)	SPECIAL - To re-appoint Mr. K.V. Chowdary (DIN: 08485334) as an Independent Director of the Company w.e.f. January 04, 2025.									
Whether promoter/ promoter group are interested in the agenda/resolution?	No									
Category	Mode of Voting	No. of shares held (1)	No. of votes polled (2)	% of Votes Polled on outstanding shares (3)=[(2)/(1)]* 100	No. of Votes – in favour (4)	No. of Votes – against (5)	% of Votes in favour on votes polled (6)=[(4)/(2)]*100	% of Votes against on votes polled (7)=[(5)/(2)]*100	Votes Invalid	Votes Abstained
Promoter and Promoter Group	E-Voting	13,77,72,090	13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		13,77,72,000	99.9999	13,77,72,000	0	100.0000	0.0000	0	0
Public- Institutions	E-Voting	10,10,08,456	8,78,42,454	86.9654	8,33,53,053	44,89,401	94.8892	5.1107	0	79,063
	Poll		0	0.0000	0	0	0.0000	0.0000	0	0
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		8,78,42,454	86.9654	8,33,53,053	44,89,401	94.8893	5.1107	0	79063
Public- Non Institutions	E-Voting	2,66,88,034	18,13,244	6.7942	18,12,883	361	99.9800	0.0199	0	490
	Poll		11,29,952	4.2339	11,29,952	0	100.0000	0.0000	0	4,990
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000	0	0
	Total		29,43,196	11.0281	29,42,835	361	99.9877	0.0123	0	5480
Total		26,54,68,580	22,85,57,650	86.0959	22,40,67,888	44,89,762	98.0356	1.9644	0	84543

Consolidated Scrutinizer's Report for Remote E-Voting and E-Voting during the AGM

[Pursuant to Section 108 of the Companies Act, 2013 (“the Act”) and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended (“the Rules”) read with Ministry of Corporate Affairs’ (MCA) General Circular No. 09/2023 dated 25th September 2023 and Regulation 44 of SEBI (LODR), Regulations, 2015]

To
Dr. Ramesh B.V. Nimmagadda
Chairman
Divi's Laboratories Limited
CIN: L24110TG1990PLC011854
1-72/23(P)/DIVIS/303, Divi Towers,
Cyber Hills, Gachibowli,
Hyderabad-500032.

The 34th Annual General Meeting (“AGM”) of the Equity Shareholders of **Divi's Laboratories Limited (‘the Company’)** having its Registered Office at 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad-500032, Telangana, held on Monday, August 12, 2024 at 10.00 A.M. (IST) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”).

Dear Sir,

I, V. Bhaskara Rao, Practicing Company Secretary (Proprietor of V. Bhaskara Rao & Co., Company Secretaries) having office at 6-2-1085/B, Flat No.105, Badam Sohana Apartments, Rajbhavan Road, Somajiguda, Hyderabad - 500082, was appointed as Scrutinizer for the purpose of scrutinizing the e-voting process (remote e-voting) and e-voting during the AGM through VC /OAVM under the provisions of Section 108 of the Companies Act, 2013 (“the Act”) read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, read with Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and in compliance with framework issued by the Ministry of Corporate Affairs through its circulars and the Secretarial Standards on General Meetings (SS-1) issued by the Institute of Company Secretaries of India, on the below mentioned resolution(s) as provided in the notice of Annual General Meeting dated May 25, 2024, (“AGM Notice”).

I submit my report as under:

1. The AGM Notice dated May 25, 2024, as confirmed by the Company was sent to the shareholders in respect of the below mentioned resolutions passed at the AGM of the Company, through electronic mode to those Members whose email addresses are registered with the Company/ Depositories, in compliance with the latest MCA General Circular No. 09/2023 dated September 25, 2023 read with Securities and Exchange Board of India (“SEBI”) Circulars dated October 06, 2023.

Page 1 of 12

2. The Shareholders holding shares as on the “cut off” date i.e. Tuesday, August 06, 2024 were entitled to vote on the resolutions.
3. The Company had appointed KFin Technologies Limited (“KFin”) as the service provider, for executing the facility of Remote E-voting and E-voting during the AGM to the shareholders of the Company. The Remote E-voting period for the business to be transacted at the AGM commenced from Thursday, August 08, 2024 from 9.00 A.M. (IST) and ended on Sunday, August 11, 2024 at 5.00 P.M. (IST). The Remote E-voting facility was unblocked by me on August 11, 2024 at 5.00 P.M. (IST).
4. The Company had also provided the e-voting facility during the AGM for the shareholders who have not casted their votes during the remote e-voting process. After seeking permission from the Chairman of the Company, e-voting during the AGM was closed/blocked in the presence of two witnesses who are not in the employment of the Company.
5. Subsequent to the completion of e-voting process at the 34th AGM, the votes cast by the shareholders were diligently scrutinized by me. The votes cast at the AGM were reconciled with the records maintained by KFin and with the authorizations lodged with the Company.
6. In respect of Remote E-Voting, the details containing, inter-alia, list of equity shareholders, who voted “For” and “Against” were downloaded from the e-voting website of KFin (<https://evoting.kfintech.com/>).
7. The Electronic data and relevant records of Voting shall remain in my safe custody until Chairman considers, approves and signs the Minutes of the aforesaid AGM and the same shall be handed over to the Company Secretary for safe custody.
8. The Management of the Company is responsible to ensure compliance with the requirements of the Act and Rules relating to remote e-voting prior to AGM and e-voting during the AGM on the resolutions contained in the AGM Notice. My responsibility as Scrutinizer for the remote e-voting and e-voting during the 34th AGM is restricted to making a Scrutinizer's Report of the votes cast in favour or against the resolutions.
9. I have completed the formalities of e-voting of the 34th AGM. I hereby submit my report (**Annexed**) and you may accordingly declare the results of the voting.

BHASKAR
A RAO
VEMURI

Digitally signed
by BHASKARA
RAO VEMURI
Date: 2024.08.12
15:32:33 +05'30'

All the resolutions stated in the AGM Notice were duly passed on consolidated results (i.e. Remote e-voting and e-voting during the 34th AGM) with requisite majority.

Thanking You,

Yours faithfully

**For V. Bhaskara Rao & Co.
Company Secretaries**

**BHASKARA
RAO VEMURI** Digitally signed by
BHASKARA RAO VEMURI
Date: 2024.08.12
15:32:50 +05'30'

**V. Bhaskara Rao
Proprietor
C.P.No: 4182, FCS No.5939
Peer Review No.670/2020
UDIN: F005939F000951466**

**KATTAMANCHI
HI
NAGARJUNA** Digitally signed by
KATTAMANCHI
NAGARJUNA
Date: 2024.08.12
15:37:49 +05'30'

Witness : K. Nagarjuna

**ANJANEYU
SALLA
LU SALLA** Digitally signed by
ANJANEYU
SALLA
Date: 2024.08.12
15:33:45 +05'30'

S. Anjaneyulu

Place: Hyderabad
Date: August 12, 2024

ANNEXURE

Resolution 1: To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2024, and the reports of the Board of Directors' and Auditors' thereon.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1420	227383575	99.51
E-voting (During AGM)	83	1129952	00.49
Total	1503	228513527	100.00

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	15	921	00.00
E-voting (During AGM)	0	0	00.00
Total	15	921	00.00

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	594562
E-voting (During AGM)	0	0
Total	11	594562

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	9	122755
E-voting (During AGM)	5	4990
Total	14	127745

Resolution 2: To declare dividend of ₹30/- per Equity Share of face value ₹2/-each (i.e. @ 1500%) for the financial year ended March 31, 2024.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1414	226948181	99.29
E-voting (During AGM)	83	1129952	00.49
Total	1497	228078133	99.78

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	24	495688	00.22
E-voting (During AGM)	0	0	0
Total	24	495688	00.22

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	594562
E-voting (During AGM)	0	0
Total	11	594562

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	6	63382
E-voting (During AGM)	5	4990
Total	11	68372

BHASKAR Digitally signed
A RAO by BHASKARA
VEMURI RAO VEMURI
 Date: 2024.08.12
 15:34:32 +05'30'

Resolution 3: To appoint a director in place of Mr. N.V. Ramana (DIN:00005031), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1379	226044138	99.19
E-voting (During AGM)	83	1129952	00.50
Total	1462	227174090	99.69

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	60	699560	00.31
E-voting (During AGM)	0	0	00.00
Total	60	699560	00.31

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	594562
E-voting (During AGM)	0	0
Total	11	594562

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	763553
E-voting (During AGM)	5	4990
Total	16	768543

BHASKAR Digitally signed
A RAO by BHASKARA
VEMURI RAO VEMURI
 Date: 2024.08.12
 15:34:53 +05'30'

Resolution 4: To appoint a director in place of Dr. Kiran S. Divi (DIN: 00006503), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1404	227162677	99.39
E-voting (During AGM)	83	1129952	00.49
Total	1487	228292629	99.88

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	36	265021	00.12
E-voting (During AGM)	0	0	00.00
Total	36	265021	00.12

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	594562
E-voting (During AGM)	0	0
Total	11	594562

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	8	79553
E-voting (During AGM)	5	4990
Total	13	84543

BHASKAR Digitally signed
A RAO by BHASKARA
VEMURI RAO VEMURI
 Date: 2024.08.12
 15:35:05 +05'30'

Resolution 5: To appoint Dr. Rajendra Kumar Premchand, (DIN: 00895990), as an Independent Director of the Company w.e.f. May 25, 2024.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1406	226591322	99.43
E-voting (During AGM)	83	1129952	00.50
Total	1489	227721274	99.93

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	27	152376	00.07
E-voting (During AGM)	0	0	00.00
Total	27	152376	00.07

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	594562
E-voting (During AGM)	0	0
Total	11	594562

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	763553
E-voting (During AGM)	5	4990
Total	16	768543

BHASKAR Digitally signed
A RAO by BHASKARA
VEMURI RAO VEMURI
 Date: 2024.08.12
 15:35:19 +05'30'

Resolution 6: To re-appoint Dr. Murali K. Divi (DIN: 00005040) as Managing Director of the Company w.e.f. October 10, 2024.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	886	201555298	88.19
E-voting (During AGM)	83	1129952	00.49
Total	969	202685250	88.68

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	552	25872400	11.32
E-voting (During AGM)	0	0	00.00
Total	552	25872400	11.32

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	594562
E-voting (During AGM)	0	0
Total	11	594562

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	8	79553
E-voting (During AGM)	5	4990
Total	13	84543

BHASKAR Digitally signed
A RAO by BHASKARA
VEMURI RAO VEMURI
 Date: 2024.08.12
 15:35:38 +05'30'

Resolution 7: To re-appoint Mr. N.V. Ramana (DIN: 00005031) as Executive Director of the Company w.e.f. December 26, 2024.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	958	206641006	90.41
E-voting (During AGM)	83	1129952	00.49
Total	1041	207770958	90.90

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	480	20786692	09.10
E-voting (During AGM)	0	0	00.00
Total	480	20786692	09.10

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	594562
E-voting (During AGM)	0	0
Total	11	594562

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	8	79553
E-voting (During AGM)	5	4990
Total	13	84543

BHASKAR Digitally signed
A RAO by BHASKARA
VEMURI RAO VEMURI
 Date: 2024.08.12
 15:36:04 +05'30'

Resolution 8: To re-appoint Mr. K.V. Chowdary (DIN: 08485334) as an Independent Director of the Company w.e.f. January 04, 2025.

(i) Voted in favour of the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	1274	222937936	97.54
E-voting (During AGM)	83	1129952	00.49
Total	1357	224067888	98.04

(ii) Voted against the resolution:

Particulars of voting	Number of members voted	Number of votes cast by them	% of total number of valid votes cast
Remote E-voting	169	4489762	01.96
E-voting (During AGM)	0	0	00.00
Total	169	4489762	01.96

(iii) Less voted:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	11	594562
E-voting (During AGM)	0	0
Total	11	594562

(iv) Abstain votes:

Particulars of voting	Number of members voted	Number of votes cast by them
Remote E-voting	8	79553
E-voting (During AGM)	5	4990
Total	13	84543

Soft copy of the list of equity shareholders who voted “FOR”, “AGAINST” and those whose votes were declared Invalid for each resolution will be emailed to the Company Secretary, after the announcement of the results by the Company.

Thanking you

Yours faithfully,

**For V. Bhaskara Rao & Co.
Company Secretaries**

BHASKARA Digitally signed by
BHASKARA RAO
RAO VEMURI
Date: 2024.08.12
VEMURI 15:36:31 +05'30'

V. Bhaskara Rao
Proprietor
C.P.No: 4182, FCS No.5939
Peer Review No.670/2020
UDIN: F005939F000951466

KATTAMAN Digitally signed
CHI by KATTAMANCHI
NAGARJUN NAGARJUNA
A Date: 2024.08.12
15:37:27 +05'30'

Witness: K. Nagarjuna

ANJANE Digitally signed
YULU by ANJANEYULU
SALLA SALLA
Date: 2024.08.12
15:36:47 +05'30'

S. Anjaneyulu

Place: Hyderabad

Date: August 12, 2024